## Kathy Keyvani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8406076/publications.pdf

Version: 2024-02-01

430843 454934 1,307 34 18 30 citations g-index h-index papers 34 34 34 2211 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Poorly differentiated chordoma with SMARCB1/INI1 loss: a distinct molecular entity with dismal prognosis. Acta Neuropathologica, 2016, 132, 149-151.	7.7	127
2	Environmental enrichment enhances cellular plasticity in transgenic mice with Alzheimer-like pathology. Experimental Neurology, 2009, 216, 184-192.	4.1	121
3	Effects of environmental enrichment on exploration, anxiety, and memory in female TgCRND8 Alzheimer mice. Behavioural Brain Research, 2008, 191, 43-48.	2.2	91
4	Activity changes and marked stereotypic behavior precede $\hat{Al^2}$ pathology in TgCRND8 Alzheimer mice. Neurobiology of Aging, 2006, 27, 955-964.	3.1	88
5	Reduction of Amyloid Angiopathy and $A\hat{l}^2$ Plaque Burden after Enriched Housing in TgCRND8 Mice. American Journal of Pathology, 2006, 169, 544-552.	3.8	81
6	Reelin Depletion is an Early Phenomenon of Alzheimer's Pathology. Journal of Alzheimer's Disease, 2012, 30, 963-979.	2.6	77
7	Exercise during pregnancy mitigates Alzheimerâ€like pathology in mouse offspring. FASEB Journal, 2012, 26, 117-128.	0.5	76
8	Amyloid- $\hat{l}^2$ dimers in the absence of plaque pathology impair learning and synaptic plasticity. Brain, 2016, 139, 509-525.	7.6	74
9	Reduction of Cerebral Oxidative Stress Following Environmental Enrichment in Mice with Alzheimerâ€Like Pathology. Brain Pathology, 2010, 20, 166-175.	4.1	73
10	Environmental Enrichment Counteracts Alzheimer's Neurovascular Dysfunction in TgCRND8 Mice. Brain Pathology, 2008, 18, 32-39.	4.1	70
11	Highly potent soluble amyloid- $\hat{l}^2$ seeds in human Alzheimer brain but not cerebrospinal fluid. Brain, 2014, 137, 2909-2915.	7.6	61
12	Preventive and therapeutic types of environmental enrichment counteract beta amyloid pathology by different molecular mechanisms. Neurobiology of Disease, 2011, 42, 530-538.	4.4	50
13	Late running is not too late against Alzheimer's pathology. Neurobiology of Disease, 2016, 94, 44-54.	4.4	36
14	Kallikreinâ€8 inhibition attenuates Alzheimer's disease pathology in mice. Alzheimer's and Dementia, 2016, 12, 1273-1287.	0.8	36
15	Loss of endothelial programmed cell death 10 activates glioblastoma cells and promotes tumor growth. Neuro-Oncology, 2016, 18, 538-548.	1.2	30
16	Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain. Frontiers in Immunology, 2020, 11, 120.	4.8	28
17	Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma. Journal of Cancer Research and Clinical Oncology, 2020, 146, 787-792.	2.5	26
18	Higher levels of kallikreinâ€8 in female brain may increase the risk for Alzheimer's disease. Brain Pathology, 2018, 28, 947-964.	4.1	20

#	Article	IF	CITATIONS
19	Glial Cells Express Nuclear Nrf2 After Fumarate Treatment for Multiple Sclerosis and Psoriasis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e99.	6.0	17
20	CSF and blood Kallikrein-8: a promising early biomarker for Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 40-48.	1.9	16
21	Leptomeningeal disease from melanomaâ€"Poor prognosis despite new therapeutic modalities. European Journal of Cancer, 2021, 148, 395-404.	2.8	16
22	$\hat{Al^2}$ dimers induce behavioral and neurochemical deficits of relevance to early Alzheimer's disease. Neurobiology of Aging, 2018, 69, 1-9.	3.1	14
23	Cerebral amyloidoma is characterized by <scp>B</scp> â€cell clonality and a stable clinical course. Brain Pathology, 2018, 28, 234-239.	4.1	14
24	The predominant expression of cancer stem cell marker ALDH1A3 in tumor infiltrative area is associated with shorter overall survival of human glioblastoma. BMC Cancer, 2020, 20, 672.	2.6	12
25	Compromised Hippocampal Neuroplasticity in the Interferon-α and Toll-like Receptor-3 Activation-Induced Mouse Depression Model. Molecular Neurobiology, 2020, 57, 3171-3182.	4.0	11
26	Machine learning-based differentiation between multiple sclerosis and glioma WHO II°-IV° using O-(2-[18F] fluoroethyl)-L-tyrosine positron emission tomography. Journal of Neuro-Oncology, 2021, 152, 325-332.	2.9	11
27	Inhibition of excessive kallikrein-8 improves neuroplasticity in Alzheimer's disease mouse model. Experimental Neurology, 2020, 324, 113115.	4.1	10
28	PDCD10-Deficiency Promotes Malignant Behaviors and Tumor Growth via Triggering EphB4 Kinase Activity in Glioblastoma. Frontiers in Oncology, 2020, 10, 1377.	2.8	9
29	Genetic knockdown of <i>Klk8</i> has sexâ€specific multiâ€ŧargeted therapeutic effects on Alzheimer's pathology in mice. Neuropathology and Applied Neurobiology, 2021, 47, 611-624.	3.2	7
30	The interaction of insoluble Amyloidâ€Î² with soluble Amyloidâ€Î² dimers decreases Amyloidâ€Î² plaque numbers. Neuropathology and Applied Neurobiology, 2021, 47, 603-610.	3.2	3
31	Simultaneous primary cancer occurrence of melanoma and pulmonary adenocarcinoma in leptomeningeal metastases: a case report. BMC Cancer, 2019, 19, 995.	2.6	1
32	Is kallikrein-8 a blood biomarker for detecting amnestic mild cognitive impairment? Results of the population-based Heinz Nixdorf Recall study. Alzheimer's Research and Therapy, 2021, 13, 202.	6.2	1
33	Response letter. Alzheimer's and Dementia, 2017, 13, 1070-1071.	0.8	O
34	NIMG-32. COMPARISON OF L-METHYL-11C-METHIONINE POSITRON EMISSION TOMOGRAPHY WITH MAGNETIC RESONANCE SPECTROSCOPY IN DETECTING NEWLY DIAGNOSED GLIOMA. Neuro-Oncology, 2018, 20, vi182-vi183.	1.2	0